156 related articles for article (PubMed ID: 22925370)
1. Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing.
Bihl MP; Foerster A; Lugli A; Zlobec I
J Transl Med; 2012 Aug; 10():173. PubMed ID: 22925370
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
Psofaki V; Kalogera C; Tzambouras N; Stephanou D; Tsianos E; Seferiadis K; Kolios G
World J Gastroenterol; 2010 Jul; 16(28):3553-60. PubMed ID: 20653064
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
Shima K; Nosho K; Baba Y; Cantor M; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
Int J Cancer; 2011 Mar; 128(5):1080-94. PubMed ID: 20473920
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
6. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
7. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
[TBL] [Abstract][Full Text] [Related]
9. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
[TBL] [Abstract][Full Text] [Related]
10. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
[TBL] [Abstract][Full Text] [Related]
11. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
[TBL] [Abstract][Full Text] [Related]
12. p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer.
Kim SH; Park KH; Shin SJ; Lee KY; Kim TI; Kim NK; Rha SY; Roh JK; Ahn JB
Cancer Res Treat; 2016 Jan; 48(1):208-15. PubMed ID: 25943321
[TBL] [Abstract][Full Text] [Related]
13. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
14. Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa.
Trzeciak L; Hennig E; Kolodziejski J; Nowacki M; Ostrowski J
Cancer Lett; 2001 Feb; 163(1):17-23. PubMed ID: 11163104
[TBL] [Abstract][Full Text] [Related]
15. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
Ye C; Shrubsole MJ; Cai Q; Ness R; Grady WM; Smalley W; Cai H; Washington K; Zheng W
Oncol Rep; 2006 Aug; 16(2):429-35. PubMed ID: 16820927
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability and survival in rectal cancer.
Samowitz WS; Curtin K; Wolff RK; Tripp SR; Caan BJ; Slattery ML
Cancer Causes Control; 2009 Nov; 20(9):1763-8. PubMed ID: 19669908
[TBL] [Abstract][Full Text] [Related]
18. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer.
Ishiguro A; Takahata T; Saito M; Yoshiya G; Tamura Y; Sasaki M; Munakata A
J Gastroenterol Hepatol; 2006 Aug; 21(8):1334-9. PubMed ID: 16872319
[TBL] [Abstract][Full Text] [Related]
19. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.
Tanaka N; Huttenhower C; Nosho K; Baba Y; Shima K; Quackenbush J; Haigis KM; Giovannucci E; Fuchs CS; Ogino S
Am J Pathol; 2010 Dec; 177(6):2731-40. PubMed ID: 21037082
[TBL] [Abstract][Full Text] [Related]
20. The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging.
Ye X; Mo M; Xu S; Yang Q; Wu M; Zhang J; Chen B; Li J; Zhong Y; Huang Q; Cai C
BMC Cancer; 2018 Oct; 18(1):1023. PubMed ID: 30348132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
